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Radioimmunotherapy (RIT) can be performed with various ra-
dionuclides. We tested the stability, biodistribution, and thera-
peutic efficacy of various radioimmunoconjugates (131I, 88/90Y,
177Lu, and 186Re) of chimeric antirenal cell cancer monoclonal
antibody G250 (mAb cG250) in nude mice with subcutaneous
renal cell cancer (RCC) tumors. Methods: The 88/90Y and 177Lu
labeling procedures of cG250 conjugated with cyclic diethyl-
enetriaminepentaacetic acid anhydride (cDTPA), isothiocyana-
tobenzyl-DTPA (SCN-Bz-DTPA), or 1,4,7,10-tetraazacyclodo-
decanetetraacetic acid (DOTA) were characterized. Stability of
the labeled conjugates in plasma at 37°C was assessed. Bio-
distribution and therapeutic efficacy of labeled cG250 were
compared in nude mice with SK-RC-52 human RCC xenografts.
Results: Both SCN-Bz-DTPA and DOTA were stable in vitro
(5% release of the radiolabel during 14 and 21 d of incubation)
and in vivo (uptake in bone  1.5 percentage injected dose per
gram [%ID/g] at 7 d after injection) when used to label 88Y or
177Lu to cG250. The DOTA conjugate was slightly but signifi-
cantly more stable than SCN-Bz-DTPA at 7 d after injection. In
vivo, these cG250 preparations showed high tumor uptake
(70  15 %ID/g  SD at 7 d after injection). Maximum tumor
uptake for 125I-cG250 and 186Re-mercaptoacetyltriglycine-
(MAG3)-cG250 (20  3 %ID/g  SD) was reached at 3 d after
injection and was much lower in comparison with cG250 labeled
with the residualizing radionuclides. Because the highest spe-
cific activities could be prepared using SCN-Bz-DTPA, and
relatively low protein doses of cG250 could be administered
without saturating the tumor, cG250-SCN-Bz-DTPA conjugates
were used in RIT studies. In RIT experiments at maximum
tolerated dose, tumor growth was delayed most effectively by
cG250 labeled with 177Lu, next most effectively by 90Y and 186Re
(which were approximately equal), and least by 131I (delayed by
approximately 185, 125, 90, and 25 d, respectively). The best
median survival (300 d) was observed for 177Lu-SCN-Bz-DTPA-
cG250. Median survival for control groups was 150 d. Con-
clusion: DOTA-conjugated radiolabeled antibodies were the
most stable radioimmunoconjugates in vitro and in vivo as
manifested by the lowest bone uptake. However, specific ac-
tivity was higher for SCN-Bz-DTPA. The RIT studies clearly
showed that the therapeutic efficacy of mAb cG250 labeled with
177Lu, 90Y, or 186Re was superior to that of 131I-cG250. The
residualizing radionuclides 177Lu and 90Y led to higher radiation
doses to the tumor and most likely are better candidates than
conventionally radiolabeled 131I for RIT with cG250 in patients
with RCC.
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The goal of this investigation was to develop an effective
radioimmunotherapy (RIT) approach for metastasized renal
cell carcinoma (RCC) using the chimeric (c) monoclonal
antibody (mAb) G250. Until now, mAb cG250 has been
labeled with 131I for RIT (1,2). Radioiodination of mAbs is
relatively easy to perform, and 131I is widely available and
relatively inexpensive. However, 131I is not an optimal ra-
dionuclide for RIT, since this radionuclide is readily re-
leased from the tumor after internalization of the mAbs and
has an abundance of high-energy -photons (Table 1),
which is a concern for radiation safety.
Residualizing radionuclides, such as 90Y and 177Lu, are
potentially more suitable radionuclides for RIT (Table 1).
The 11-mm tissue penetration range of the -emissions
of 90Y is much higher than the comparable 3-mm range of
131I. Apart from some bremstrahlung, 90Y does not emit
-photons, so there is less need for patient shielding after
high-dose treatment. The limitation of 90Y is the inability
to scintigraphically visualize the distribution of the ther-
apeutic dose throughout the body. The 2-mm range of the
-particles of 177Lu is of the same order as the range of
131I -particles. The physical characteristics of 177Lu
-photons (208 keV, 11% abundancy) are ideal for im-
aging and also from a radiation safety point of view.
Because of the range of -particles, 90Y seems particu-
larly well suited for the treatment of relatively large solid
tumor masses, and 177Lu may have an advantage in treat-
ing small lesions (3).
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When released from the antibody, the metallic radionu-
clides 90Y and 177Lu are partly incorporated into the mineral
bone (4), which may lead to excessive radiation to the bone
marrow (5). To prevent in vivo dissociation of 90Y and 177Lu
from the antibody, various chelates have been developed
and tested both in vitro and in vivo. Initially, cyclic anhy-
dride diethylenetriaminepentaacetic acid (cDTPA) was used
to label mAbs with 90Y, because this chelate formed very
stable complexes with 111In (6). However, mAbs labeled
with 90Y via this chelate were unstable, leading to excessive
accumulation of released 90Y in the bone (5,7). Therefore,
bifunctional chelates based on DTPA (e.g., isothiocyanato-
benzyl-DTPA [SCN-Bz-DTPA] and macrocyclic chelates
such as 1,4,7,10-tetraazacyclododecanetetraacetic acid [DOTA])
were developed for mAb-labeling purposes (7–10).
In addition to high stability and retained immunoreactiv-
ity after radiolabeling, the specific activity that can be
obtained is also important in selecting a suitable chelate,
especially in RIT of RCC with cG250. The most optimal
protein dose for tumor targeting with cG250 is relatively
low compared with other mAb-antigen systems. We have
shown in patients with RCC that high uptake in the tumor
(expressed as percentage injected dose per gram [%ID/g])
could be obtained only if the total cG250 protein dose per
patient did not exceed 10 mg (1). For 90Y- or 177Lu-labeled
antibodies in RIT in humans, one would aim to administer
an activity dose of 1,110–2,220 MBq (30–60 mCi) 90Y or
5,550–7,400 MBq (150–200 mCi) 177Lu. This implies that
for a protein dose of 5–10 mg, a specific activity  370
MBq/mg (10 mCi/mg) is a prerequisite for RIT with
cG250 in patients with RCC.
Another radionuclide that has become available for RIT
is 186Re, with a -particle range of 5 mm (Table 1). It has
chemical properties similar to those of 99mTc, and the energy
of the emitted -photons is similar as well. 186Re is therefore
well suited for imaging with a -camera. As with 177Lu, the
limited percentage of -emissions (9%) of 186Re provides a
major advantage from a radiation safety point of view, and
the in vivo distribution of a therapeutic dose of 186Re-
labeled antibody can be imaged scintigraphically. Several
186Re mAb-labeling methods have been described. The di-
rect labeling method described by Griffiths et al. (11) results
in low 186Re-to-mAb molar ratios, and the 186Re–mAb com-
plex is unstable in vivo. The indirect labeling method de-
scribed by Fritzberg et al. (12) and optimized by Visser et
al. (13) using mercaptoacetyltriglycine (MAG3) as a chelate
yielded relatively high 186Re-MAG3–to–mAb molar ratios,
resulting in higher specific activities, and is suitable for RIT
purposes. The -emitter 188Re is less suited for RIT with
IgG mAbs. The physical half-life (17 h) does not match with
the relatively slow pharmacokinetics and tumor accretion of
cG250 IgG (1).
To determine the most optimal radioimmunoconjugate to
be labeled with mAb cG250 for RIT in humans, a series of
experiments was designed. First, the in vitro and in vivo
characteristics of cG250 labeled with 90Y and 177Lu using 3
different chelates (cDTPA, SCN-Bz-DTPA, and DOTA)
were directly compared. The labeling efficiency, in vitro
stability, and immunoreactivity of each of the labeled im-
munoconjugates were determined. Subsequently, the biodis-
tribution of these radioimmunoconjugates was studied and
compared with the biodistribution of 125I-cG250 and 186Re-
MAG3-cG250 in nude mice with subcutaneous SK-RC-52
human RCC xenografts. Finally, the therapeutic efficacies
of maximum tolerable activity doses (MTDs) of 90Y-SCN-
Bz-DTPA-cG250, 177Lu-SCN-Bz-DTPA-cG250, 131I-cG250,
and 186Re-MAG3-cG250 were studied.
MATERIALS AND METHODS
Monoclonal Antibody cG250
The isolation and immunohistochemical reactivity of mAb
G250 have been described elsewhere (1,14). To reduce the immu-
nogenicity of the antibody, a chimeric version has been developed
(15). MAb cG250 is reactive with the antigen G250 (Ka  4 109
L/mol), which has been identified as the tumor-associated isoen-
zyme carbonic anhydrase isoenzyme IX (MN/CA IX) (16). It is
expressed on the cell surface of nearly all clear-cell RCCs and is
absent on most other normal tissues and malignancies
(1,14,17,18). The majority of RCCs (75%) are of the clear-cell
type (14,16).
Conjugation, Radiolabeling, and Quality Control
The conjugation of cDTPA (Fig. 1A) (Sigma) and SCN-Bz-
DTPA (Fig. 1B) (Macrocyclics) to mAb cG250 was performed in
a 0.1-mol/L NaHCO3 buffer with pH 8.2 and using a 100-
(cDTPA) or 50-fold (SCN-Bz-DTPA) molar excess, as described
by Ruegg et al. (19) with minor modifications (conjugation period
TABLE 1
Characteristics of Radionuclides
Radionuclide
Half-life
(days)
-Radiation -Radiation
Emax (MeV) Abundancy keV Abundancy
131I 8 0.6 89% 364 81%
90Y 2.7 2.28 100%
177Lu 6.7 0.5 79% 208 11%
0.18 12% 113 6%
186Re 3.8 1.08 71% 137 9%
0.9 22%
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of 1 h at room temperature). cDTPA served as a reference for the
2 other immunoconjugates used (SCN-Bz-DTPA-cG250 and
DOTA-cG250), because it is known that conjugation of cDTPA to
mAbs leads to unstable radioimmunoconjugates when labeled with
90Y or 177Lu. The cDTPA-cG250 and SCN-Bz-DTPA-cG250 con-
jugates were labeled with either 88Y (Isotope Products Europe
Blaseg) or 90Y (Perkin Elmer) or 177Lu (University of Missouri
Research Reactor) in a 0.1 mol/L ammonium acetate buffer of pH
5.4 for 30 min at room temperature. For the in vitro stability tests
and biodistribution experiments, the -emitter 88Y was substituted
for 90Y. Similarly, 125I was used instead of 131I in the biodistribu-
tion experiments.
The activation and conjugation of DOTA (Fig. 1C) was per-
formed as described by Lewis et al. (20). The DOTA-cG250
conjugate was labeled with either 88/90Y or 177Lu in an ammonium
acetate buffer with pH 5.4 for 60 min at 45°C. The number of
DTPA or DOTA ligands per cG250 molecule was determined as
described by Hnatowich et al. (6).
MAb cG250 was radioiodinated with 125I (Amersham) and 131I
(MDS Nordion) according to the IODO-GEN method (Pierce)
(1,21). The labeling of the MAG3 chelate with 186Re (Mallinck-
rodt) and the conjugation of the radioactive chelate to mAb cG250
were performed essentially as described by Visser et al. (12).
All conjugation and labeling procedures using 177Lu or 88/90Y
were performed under strict metal-free conditions. All radiolabeled
cG250 preparations were purified by gel filtration on a PD-10
column (Amersham Pharmacia Biotech) and eluted with phos-
phate-buffered saline (PBS) supplemented with 0.5% bovine se-
rum albumin (BSA). For all preparations, the amount of non–
mAb-bound radiolabel was determined by instant thin-layer
chromatography (ITLC) using ITLC silica gel strips (Gelman
Sciences, Inc.), using 0.1 mol/L citrate buffer (pH 6.0) as the
mobile phase (Rf 0 for radioimmunoconjugates, and Rf 0.8–1
for free and chelated radionuclides).
The immunoreactive fraction at infinitive antigen excess of all
radiolabeled cG250 preparations was determined on freshly
trypsinized SK-RC-52 RCC cells essentially as described by
Lindmo et al. (22), with minor modifications (1).
In Vitro Stability
The stabilities of the various 88Y- and 177Lu-labeled prepara-
tions were assessed in vitro by diluting in plasma at an activity
concentration of 18.5 kBq/mL (0.5 Ci/mL) for the 88Y prepara-
tions and 1,850 kBq/mL (50 Ci/mL) for the 177Lu preparations. A
final concentration of 0.5 mmol/L ethylenediaminetetraacetic acid
(EDTA) was added to capture released radiometal, and the prep-
arations were incubated at 37°C. Plasma samples were analyzed at
0 and 4 h and at 1, 2, 5, 7, 9, 12, 15, 19, and 22 d by fast protein
liquid chromatography (FPLC) using a Biosep Sec-S3000 gel
filtration column (Phenomenex). In a previous study, we demon-
strated that 131I-cG250 and 186Re-MAG3-cG250 were stable (5%
release of the radiolabel) in plasma up to 30 h using the same
method (21).
Nude Mouse Tumor Model
The RCC cell line SK-RC-52 was derived from a mediastinal
metastasis of a primary RCC and has been described elsewhere
(23). SK-RC-52 cells were cultured in RPMI medium (Life Tech-
nologies) supplemented with 10% fetal calf serum (FCS) at 37°C
in a humidified atmosphere with 5% CO2. Cells were washed in
saline, trypsinized, and washed in RPMI	 10% FCS, and 2 106
cells (in 0.2 mL of RPMI medium) were injected subcutaneously
into the right flank of 6- to 8-wk-old BALB/c nu/nu mice. Bio-
distribution and RIT experiments were initiated 14–16 d after
inoculation of tumor cells. All animal experiments were approved
by the Animal Experiments Committee of the University Medical
Center Nijmegen and performed in accordance with its guidelines.
Biodistribution Experiments
To study the biodistribution of the various 88Y-labeled immu-
noconjugates, RCC-tumor-bearing mice (median tumor weight,
0.08 g) were divided randomly into groups of 15 mice. Mice were
injected intravenously with 37 kBq (1 Ci) 88Y-cDTPA-cG250 or
88Y-SCN-Bz-DTPA or 22.2 kBq (0.6 Ci) 88Y-DOTA-cG250,
each diluted in PBS 	 0.5% BSA. In a similar experiment, mice
were injected intravenously with 185 kBq (5 Ci) 177Lu-cDTPA-
cG250, 177Lu-SCN-Bz-DTPA-cG250, or 177Lu-DOTA-cG250.
Also, 2 groups of 15 mice were injected intravenously with 185
kBq (5 Ci) 125I-cG250 or 1,850 kBq (50 Ci) 186Re-MAG3-
cG250. All mice received a protein dose of 25–50 g cG250
(volume, 200 L/mouse). In each group, 5 mice were killed at 1,
3, or 7 d after injection, and the biodistribution of the radiolabel
was determined. The tumor and normal tissues (blood, muscle,
femur without marrow, lung, spleen, kidney, liver, and small
intestines without contents) were dissected, weighed, and counted
in a -counter (Wizard; Pharmacia-LKB). To correct for radioac-
tive decay, injection standards were counted simultaneously. The
activity in samples was expressed as %ID/g tissue.
Maximum Tolerated Dose
The MTD of every radiolabeled cG250 preparation in mice was
determined. BALB/c nu/nu mice (6–8 wk old, 5 per group) were
injected intravenously with escalating doses of 131I-cG250 (7.4,
11.1, 14.8, 18.5, or 22.2 MBq [200, 300, 400, 500, or 600 Ci]),
90Y-SCN-Bz-DTPA-cG250 (2.8, 3.7, 4.6, 5.6, 6.5, 7.4, or 11.1
MBq [75, 100, 125, 150, 175, 200, or 300 Ci]), or 177Lu-SCN-
Bz-DTPA-cG250 (19.4, 22.2, 25.9, or 29.6 MBq [525, 600, 700, or
800 Ci]). The MTD for 186Re-MAG3-cG250 was derived from
FIGURE 1. Structure of the ligands used:
cDTPA (A), SCN-Bz-DTPA (B), and DOTA
(C).
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similar experiments obtained with another intact IgG mAb used
simultaneously at our department (9.3, 13.0, 18.5, or 24.1 MBq
[250, 350, 500, or 650 Ci]). After injection, the mice were
weighed and survival was monitored twice weekly during 2 mo.
MTD was set 1 dose level below the dose level leading to 20%
decrease in total body weight in at least 1 of the mice or early death
of at least 1 mouse.
Dosimetry
Radiation dose estimates to the tumors of mice in the RIT
experiments were determined by integrating the trapezoidal re-
gions defined by the time–activity data from the biodistribution
experiments. The resulting integral was converted to mGy/MBq
using S values (MIRDOSE3; unit density sphere model) appropri-
ate for each radionuclide and assuming a tumor weight of 0.055 g,
corresponding approximately to the mean tumor volume at the
start of the RIT experiments (51 mm3) (24). Mean absorbed dose
in the tumor was further calculated by multiplying by the respec-
tive MTD of each radiolabeled cG250 preparation. Absorbed dose
in the tumor was calculated for 90Y using the 88Y biodistribution
data and for 131I using the 125I biodistribution data.
Radioimmunotherapy Experiments
Based on the results of the radiolabeling and biodistribution
studies, SCN-Bz-DTPA was selected instead of DOTA as a chelate
for labeling 90Y and 177Lu to cG250 in subsequent RIT experi-
ments. High specific activities, a necessity for RIT experiments
with cG250 in humans, could be obtained with SCN-Bz-DTPA,
and biodistribution experiments in mice showed only a slight
advantage for the DOTA conjugates.
RIT studies were performed on nude mice (10 per group) with
small (mean volume, 51  35 mm3) subcutaneous SK-RC-52
tumors. Mice received cG250 labeled with 131I, 90Y-SCN-Bz-
DTPA, 177Lu-SCN-Bz-DTPA, or 186Re-MAG3 intravenously at
MTD (protein doses of 30, 30, 60, and 35 g per mouse, respec-
tively). Mice in control groups received unlabeled cG250, PBS, or
5.6 MBq (150 Ci) 90Y-SCN-Bz-DTPA-cU36, the last serving as
an irrelevant control mAb in this study (protein dose of 30 g per
mouse for the 2 cG250 groups) (25). In this tumor model, a cG250
antibody protein dose  60 g was used to avoid a decrease of
tumor uptake at higher protein doses as a result of saturation of
accessible antigens in the tumor. In separate biodistribution studies
in nude mice with subcutaneous SK-RC-52 tumors injected with
variable protein doses of cG250 (3, 10, 30, 60, 90, 100, or 300 g),
only at protein doses  90 g was cG250 uptake in RCC tumors
decreased (unpublished data, 2003).
Tumor size was measured in 3 dimensions twice weekly with a
caliper for the first 100 d and once each week thereafter. Tumor
volume was calculated as:
Volume  4/3  
  r1  r2  r3,
where r is tumor radius, expressed in cubic millimeters. When
tumor volume exceeded 2 cm3, mice were killed for humane
reasons. Survival curves according to the Kaplan–Meier method
were generated for each group. Mean tumor growth over time per
group was calculated and expressed as relative tumor growth:
tumor volume (V) divided by tumor volume at day 0 (V0). When
a mouse died or was killed during the experiment, its last observed
tumor volume was used to calculate the mean tumor growth curve
in the corresponding group. The delay in exponential tumor growth
(expressed in days) for each mouse was determined as follows. If
tumor volume increased without a temporary delay in the individ-
ual tumor growth curve after injection of one of the preparations,
then tumor growth delay was set at 0 d. This was the case in most
mice in the control groups (unlabeled cG250, PBS, and 90Y-cU36).
In the groups that received radiolabeled cG250, most often a
temporary maximum tumor volume was reached in the first 50 d
after injection, expressed as V1max on day d1. In subsequent days,
the tumor volume decreased, after which the tumor volume in-
creased again. The day on which V1max was reached for the
second time was determined and designated as day d2. The delay
in exponential tumor growth was defined as and calculated by
subtracting d1 from d2. For each group, mean and SD of exponen-
tial tumor growth delay were calculated.
Statistical Analysis
Statistical analysis of bone uptake in the biodistribution exper-
iments was performed using Bonferroni-corrected, repeated-mea-
sures, 1-way ANOVA. The software package SPSS version 10.0
(SPSS Inc.) was used for statistical analysis of the RIT experi-
ments. Because of lack of homogeneity of variances, the nonpara-
metric procedure of Kruskal–Wallis was applied to look for sig-
nificant differences in exponential tumor growth delay between the
groups. Kaplan–Meier survival curves were analyzed for differ-
ences using the log-rank test. Differences were considered signif-
icant when P  0.05 (2-sided).
RESULTS
Conjugation, Radiolabeling, and Quality Control
From 1 to 3 DTPA/DOTA moieties were conjugated per
IgG molecule. Table 2 shows the maximum specific activity
that could be obtained with each of the immunoconjugates.
The maximum specific activity of the DOTA radioimmu-
noconjugates was approximately half the value that could be
obtained with the cDTPA-cG250 and SCN-Bz-DTPA-
cG250 conjugates. The radiochemical purity after PD-10
purification was always 95%, except for the cDTPA ra-
dioimmunoconjugates (Table 2). All preparations retained
their immunoreactivity (Table 2).
Approximately 2 MAG3 moieties were conjugated per
cG250 molecule. A specific activity of 518 kBq/g (14
Ci/g) was obtained for 186Re-MAG3-cG250 and 370
kBq/g (10 Ci/g) for 131I-cG250. The immunoreactivity
immediately after labeling was 95% for both 131I-cG250
and 186Re-MAG3-cG250 (Table 2).
In Vitro Stability
FPLC analysis of the preparations after incubation in
human plasma indicated that all DOTA and SCN-Bz-DTPA
preparations were quite stable, because 5% of the radio-
label was released during 14 d of incubation (Fig. 2).
88Y-DOTA-cG250 and 177Lu-DOTA-cG250 were even
more stable, showing 5% release during the complete
incubation period (22 d) (Fig. 2). As expected, both cDTPA
preparations were unstable in vitro, showing 10% release
of the radiolabel in the first 24 h (Fig. 2).
Biodistribution Experiments
Biodistribution studies in nude mice with subcutaneous
SK-RC-52 tumors showed relatively low blood levels for
the 88Y-cDTPA-cG250 preparation when compared with
330 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 45 • No. 2 • February 2004
88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-cG250, as a re-
sult of the known instability of the former preparation
(blood levels of 1.5 %ID/g versus 8.4 %ID/g and 8.2 %ID/g
at 7 d after injection, respectively) (Table 3). Conversely,
bone uptake was much higher for 88Y-cDTPA–labeled
cG250 than for 88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-
cG250 (10.7  2.4 %ID/g versus 1.2  0.2 %ID/g and
0.4  0.3 %ID/g at 7 d after injection, respectively) (Table
3). Although femur uptake was low for both 88Y-SCN-Bz-
DTPA-cG250 and 88Y-DOTA-cG250, indicating high sta-
bility of both radioimmunoconjugates, the difference be-
came significant at 7 d after injection (P  0.05). Both the
88Y-SCN-Bz-DTPA– and the 88Y-DOTA–labeled cG250
preparation showed high uptake in tumor (52  7 %ID/g
and 44  15 %ID/g at 3 d after injection, with a further
increase to 71  8 %ID/g and 55  11 %ID/g at 7 d after
injection) (Fig. 3; Table 3). Uptake in other tissues at 7 d
after injection was low and very similar for 88Y-SCN-Bz-
DTPA-cG250 and 88Y-DOTA-cG250. The results of the
177Lu-labeled cG250 preparations were comparable with
those obtained with the 88Y-labeled cG250 preparations.
The difference in bone uptake between 177Lu-SCN-DTPA-
cG250 and 177Lu-DOTA-cG250 was significant at all 3 time
points (P  0.001). Tumor uptake of 177Lu-SCN-Bz-DTPA
and 177Lu-DOTA-cG250 was not significantly higher com-
pared with groups that received the corresponding 88Y-
labeled cG250 immunoconjugates at 7 d after injection.
However, uptake of 177Lu-SCN-Bz-DTPA-cG250 generally
was higher in normal tissues than was uptake of 177Lu-
DOTA-cG250 and significantly higher in spleen and liver at
3 and 7 d after injection (P  0.0001). This phenomenon
was not observed in the cG250 immunoconjugates labeled
with 88Y (Table 3).
In contrast, uptake of 125I-cG250 was much lower in all
tissues, especially in tumor (maximally 14 3 %ID/g at 3 d
after injection), whereas blood levels were similar compared
with 88Y/177Lu-SCN-Bz-DTPA/DOTA-cG250, indicating a
washout of the radioiodine label from the tumor (Table 3;
Fig. 3). The biodistributions of 186Re-MAG3-cG250 and
125I-cG250 were nearly identical (Table 3; Fig. 3).
Dosimetry
For the various preparations, mean absorbed doses in the
tumors at MTD were estimated as 76 Gy for 131I-cG250, 95
Gy for 90Y-SCN-Bz-DTPA-cG250, 104 Gy for 186Re-
MAG3-cG250, and 807 Gy for 177Lu-SCN-Bz-DTPA-
cG250 (Table 4).
Radioimmunotherapy Experiments
The MTDs of the various labeled cG250 preparations
were 11.1 MBq (300 Ci) for 131I-cG250, 5.6 MBq (150
Ci) for 90Y-SCN-Bz-DTPA-cG250, and 18.5 MBq (500
Ci) for both 177Lu-SCN-Bz-DTPA-cG250 and 186Re-
MAG3-cG250. Within 10 d after intravenous injection of
the various preparations at MTD, 2 mice died unexpectedly:
one in the 177Lu group and another in the PBS control group.
These deaths were not considered related to the injections,
and these 2 mice were excluded from analysis. The survival
curves (Fig. 4) show that the median survivals of the groups
that received 177Lu-SCN-Bz-DTPA, 90Y-SCN-Bz-DTPA-
cG250, 186Re-MAG3-cG250, and 131I-cG250 were signifi-
cantly longer (294, 241, 211 and 164 d, respectively) than
those of the unlabeled cG250, PBS, and 90Y-cU36 control
groups (range, 83–143 d) (P  0.001).
TABLE 2
Characteristics of Radiolabeled Immunoconjugates
Preparation
Maximum specific activity
in kBq/g (Ci/g)
Labeling
efficiency (%)
RCP after
purification (%)
Immunoreactivity
(%)
90Y-cDTPA-cG250 370 (10) 13 86 ND
90Y-SCN-Bz-DTPA-cG250 370 (10) 90 98 100
90Y-DOTA-cG250 111 (3) 94 98 80
177Lu-cDTPA-cG250 296 (8) 15 75 89
177Lu-SCN-Bz-DTPA-cG250 296 (8) 97 98 82
177Lu-DOTA-cG250 111 (3) 94 99 87
131I-cG250 1,850 (50) 87 98 96
186Re-MAG3-cG250 307 (8) 43 99 95
RCP  radiochemical purity; ND  not determined.
FIGURE 2. In vitro stability analyses using fast protein liquid
chromotography for 88Y-X-cG250 (A) and 177Lu-X-cG250 (B)
conjugated with 1 of 3 chelates: cDTPA, SCN-Bz-DTPA, or
DOTA.
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Figures 5 and 6 show tumor growth curves of all indi-
vidual mice, and Figure 7 shows the mean relative tumor
growth per group. Individual mouse curves indicate that
90Y-, 186Re, and 177Lu-labeled cG250 treatments initiated the
longest median delays of exponential tumor growth (Table
5). Mice in the 3 control groups did not show a statistically
significant difference in exponential tumor growth delay
(overall mean, approximately 8 d). In subsequent statistical
analysis, therefore, mice in the 3 control groups were
pooled. Treatment with 177Lu-SCN-Bz-DTPA-cG250 re-
sulted in the longest delay in tumor growth (approximately
200 d). This was significantly longer than the delays ob-
served with 90Y-SCN-Bz-DTPA-cG250 (P  0.016) and
186Re-MAG3-cG250 (P  0.001). The 90Y-labeled cG250
group did not differ significantly (P  0.38) from the
186Re-labeled cG250 group in tumor growth delay (125 and
90 d, respectively). These 2 groups differed significantly
(P  0.001) from the group treated with 131I-cG250 (tumor
growth delay of 27 d), which again differed significantly
from the control groups (P  0.001).
DISCUSSION
To directly compare the therapeutic efficacy of the cG250
antibody labeled with 131I, 90Y, 177Lu, or 186Re, we first
determined the most suitable chelate and conjugation pro-
cedure for labeling the antibody with 88/90Y or 177Lu. The in
vitro stability of DOTA was slightly better than that of
SCN-Bz-DTPA, with the difference between the 2 conju-
TABLE 3
Biodistribution of Radiolabeled cG250 Immunoconjugates*
Organ
Days
after
injection†
Preparation
88Y-cDTPA
88Y-SCN-
Bz-DTPA 88Y-DOTA
177Lu-
cDTPA
177Lu-SCN-
Bz-DTPA
177Lu-
DOTA 125I
186Re-
MAG3
Tumor 1 32.9  7.2 34.8  8.5 36.2  14.1 34.6  10.8 53.2  21.1 41.3  9.9 11.7  1.5 13.5  1.8
3 46.6  19.7 51.9  7.0 44.4  14.8 59.0  11.5 113.3  24.7 86.9  14.5 14.0  3.0 16.9  2.8
7 27.4  4.8 70.9  8.4 55.3  10.7 45.0  30.0 87.3  14.0 74.5  10.5 9.1  2.0 7.9  2.0
Muscle 1 0.8  0.1 1.3  0.4 1.3  0.2 1.1  0.3 1.4  0.1 1.2  0.2 1.4  0.1 1.2  0.4
3 0.5  0.1 1.2  0.2 1.4  0.2 0.6  0.2 1.1  0.2 1.1  0.1 1.0  0.1 1.1  0.3
7 0.2  0.1 0.9  0.3 0.7  0.2 0.3  0.1 0.6  0.2 0.6  0.1 0.6  0.2 0.5  0.2
Blood 1 12.8  0.9 16.4  2.3 15.2  3.2 16.5  1.4 21.0  1.4 14.9  1.2 16.9  0.9 17.3  1.4
3 5.9  0.8 11.8  2.9 12.5  1.3 6.7  0.5 13.4  3.8 11.3  1.2 12.4  1.3 14.8  1.5
7 1.5  0.2 8.4  1.8 8.2  1.9 1.6  1.0 5.9  1.7 6.0  1.6 6.8  1.6 6.7  1.0
Femur 1 6.3  1.1 1.1  0.5 0.7  0.2 5.2  1.2 1.3  0.3 0.6  0.2 0.7  0.1 0.5  0.2
3 10.7  1.3 1.3  0.6 1.0  0.2 11.0  2.7 1.3  0.3 0.2  0.1 0.5  0.0 0.4  0.1
7 10.7  2.4 1.2  0.2 0.4  0.3 14.2  4.7 1.5  0.3 0.3  0.2 0.4  0.2 0.2  0.1
Spleen 1 3.7  0.6 3.4  0.6 2.7  0.4 5.2  2.0 5.5  0.9 3.4  0.5 2.9  0.2 2.7  0.4
3 3.4  0.9 2.9  0.6 2.8  0.3 4.2  0.8 6.3  1.5 3.2  0.5 2.1  0.4 2.6  0.4
7 2.5  0.5 3.0  0.4 2.4  0.3 4.8  2.1 6.6  2.1 2.9  0.2 1.2  0.3 1.0  0.1
Kidney 1 7.1  0.6 4.8  0.6 4.8  0.8 7.7  0.5 6.7  0.5 4.7  0.4 4.4  0.3 4.5  0.2
3 5.8  0.7 3.9  0.7 4.5  0.5 6.1  0.9 4.1  1.3 3.8  0.4 3.2  0.3 3.6  0.3
7 3.9  0.8 2.6  0.4 2.7  0.6 3.7  0.9 2.4  0.3 2.2  0.4 1.8  0.5 1.7  0.3
Liver 1 6.5  0.7 5.8  0.9 5.7  0.6 9.0  0.5 10.4  3.2 4.5  0.4 3.7  0.1 4.8  0.5
3 5.3  0.2 5.9  0.3 7.0  0.7 10.1  3.1 16.6  5.6 4.2  0.4 2.8  0.1 3.5  0.4
7 4.9  1.2 4.2  0.6 3.7  0.4 8.6  2.1 16.7  2.1 4.0  0.6 1.7  0.5 1.6  0.4
Intestine 1 3.7  1.1 2.5  0.4 2.4  0.6 3.4  1.0 3.8  1.1 2.4  0.8 3.5  0.6 3.2  0.7
3 2.3  0.8 1.8  0.4 2.1  0.4 2.2  0.4 2.8  0.8 1.9  0.5 2.8  0.5 2.5  0.6
7 0.8  0.2 1.4  0.3 1.7  0.3 1.2  0.3 1.5  0.3 1.4  0.4 1.3  0.3 1.2  0.3
*Values given as %ID/g tissue  SD.
†Protein doses in the radiolabeled preparations were 50 g each for 88Y-cDTPA, 88Y-DOTA, 88Y-SCN-Bz-DTPA, and 186Re-MAG3; 30 g
each for 177Lu-cDTPA, 177Lu-SCN-Bz-DTPA, and 177Lu-DOTA; and 16 g for 125I.
FIGURE 3. Biodistribution results of uptake in tumor of 88Y-
and 177Lu-labeled cDTPA, SCN-Bz-DTPA, and DOTA-cG250;
125I-cG250; and 186Re-MAG3-cG250 at 1, 3, and 7 d after injec-
tion.
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gates becoming apparent only after14 d incubation. How-
ever, in our study the higher stability of the DOTA-chelated
radiometallic mAbs resulted in a significantly lower femur
uptake compared with SCN-Bz-DTPA–chelated cG250 at
7 d after injection. This is in agreement with the results of
Camera et al. (26), who reported virtually no release of 88Y
from p-nitrobenzyl-DOTA (2B-DOTA) (0.5%  0.06%),
whereas only a 5% release of activity was noted for 2
DTPA-derivative chelates 2-(p-SCN-Bz)-cyclohexyl-DTPA
(A isomer) and 2-(p-SCN-Bz)-6-methyl-DTPA after 17 d of
incubation in serum. Nevertheless, in vivo this resulted in a
significantly higher cortical bone uptake for the DTPA-
derivative chelates than for DOTA (2.8  0.2 %ID/g and
3.0  0.3 %ID/g versus 1.2  0.1 %ID/g at 7 d after
injection, respectively) (26). Govindan et al. (27) reported a
more marked difference in the in vitro stability of 90Y-
DOTA and 90Y-Bz-DTPA, with a 0.4% versus 10.7% re-
spective dissociation after 11 d incubation in serum. This
also resulted in similar tumor and tissue uptake in nude mice
bearing human B-cell lymphoma xenografts over a 10-d
period, with the exception of bone uptake, which was up to
50% lower for 88Y-DOTA-hLL2 than for 88Y-Bz-DTPA-
hLL2 (27). Whether DOTA is also superior for 177Lu has not
been shown conclusively. Stein et al. (28) used DOTA as
the chelate for facile and stable radiolabeling of mAb RS7
with 177Lu and 88Y and observed nearly identical biodistri-
bution results for the radionuclides as did we when using
DOTA as the chelate. On the other hand, Milenic et al. (10)
performed a comparison of the performance of the SCN-
Bz-DTPA and DOTA ligands as chelates to radiolabel mAb
CC49 with 177Lu. In biodistribution studies, these research-
ers observed no apparent significant differences between the
conjugates tested, suggesting similar stabilities. Based on
improved labeling efficiency and immunoreactivity, they
prefered SCN-Bz-DTPA as the chelate for radiolabeling
mAbs with 177Lu for RIT applications (10). The biodistri-
butions of 177Lu-SCN-Bz-DTPA-cG250 and 177Lu-DOTA-
cG250 observed in our study provide evidence that there
might be a slight difference in in vivo stability between
these 2 immunoconjugates, because uptake of 177Lu-SCN-
Bz-DTPA-cG250 was slightly higher in most tissues, in-
cluding bone, and markedly higher in liver and spleen.
However, we did not observe this phenomenon in the cor-
responding 88Y-labeled cG250 groups, except for a slight
difference in uptake in bone, and the in vitro stability did not
show a difference between SCN-Bz-DTPA and DOTA
when labeled with 88Y or 177Lu. Furthermore, the liver and
spleen uptake of 177Lu-SCN-Bz-DTPA-cG250 was unex-
pectedly higher than even 177Lu-cDTPA-cG250. Therefore,
we are cautious to draw conclusions about the in vivo
stability of the 177Lu-SCN-Bz-DTPA-cG250 group.
We used the same considerations as Milenic et al. (10)
when we proceeded with the immunoconjugate SCN-Bz-
DTPA-cG250 for RIT of RCC. Because higher specific
activities could be obtained with the SCN-Bz-DTPA-cG250
conjugate, we used this immunoconjugate for subsequent
RIT experiments in nude mice with subcutaneous RCC
tumors. When labeling DOTA conjugates with 90Y or 177Lu,
traces of metal ions competing for complexation with
DOTA apparently limit the maximum specific activity that
can be obtained. So far, the requirement of a high specific
activity (10 mCi/mg) could be met only when derivatized
DTPA was used as a chelate.
RIT studies in nude mice with subcutaneous RCC xeno-
grafts demonstrated that the therapeutic efficacy of cG250
labeled with 177Lu or 90Y was superior to that of 131I-cG250.
This is in line with our observations in the biodistribution
studies: Tumor uptake with these residualizing radionu-
TABLE 4
Calculated Mean Absorbed Dose in Tumors at Maximum Tolerated Dose (MTD)
Radioimmunoconjugate
preparation
Self-dose S value*
(mGy/MBq . s)
AUC
(h)
Absorbed tumor dose
(Gy)
131I-cG250 1.305 29.16 76
186Re-MAG3-cG250 1.9215 16.30 104
90Y-SCN-Bz-DTPA-cG250 2.055 46.17 95
177Lu-SCN-Bz-DTPA-cG250 1.2035 201.44 807
*For tumors of 0.055 g (MIRDOSE3, unit density sphere model) (24).
AUC  area under the curve.
FIGURE 4. Survival curves of groups treated at MTD (131I-
cG250, 186Re-MAG3-cG250, 90Y-ITC-Bz-DTPA-cG250, and
177Lu-ITC-Bz-DTPA-cG250 groups), and controls (unlabeled
cG250, PBS, and 5.6 MBq [150 mCi] 90Y-cU36 groups).
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clides was approximately 4 times higher than tumor uptake
obtained with radioiodinated cG250. Numerous studies
have demonstrated that the enhanced uptake of radionu-
clides such as 111In and 90Y is the result of intracellular
retention of the radiolabeled catabolites after internalization
of the radiolabeled antibody (29–32). In contrast, the lyso-
somal degradation product of radioiodinated mAbs, 131I-
tyrosine, is released from the target cell (29,31). As a result
of the longer retention time of residualizing radionuclides in
the tumor, higher radiation doses to the tumor are achieved,
leading to an enhanced antitumor effect (29,33,34). Various
radioiodination methods have now been developed that
improve the intracellular retention of the iodine label in the
target cell (29,31,32,35,36)). It might be worthwhile to
consider these methods for labeling cG250 with 131I. How-
ever, the physical disadvantages of 131I, including relatively
long half-life and high-energy -photons, would still re-
main.
The intracellular effect of a 186Re-MAG3–labeled mAb
on cell binding and internalization still needs to be eluci-
dated. According to our observations in the biodistribution
experiments, 186Re-MAG3-cG250 showed a pattern nearly
identical to that of 131I-cG250, resulting in low tumor ac-
cretion and more rapid washout of the radiolabeled antibody
preparation from the tumor (maximum tumor uptake, 17
%ID/g at 3 d after injection), which is similar to earlier
results (21,37). Nevertheless, the results of the RIT exper-
iments did show a difference in these 2 preparations. Al-
though 131I-cG250 showed a significantly shorter delay in
tumor growth compared with 90Y- and 177Lu-labeled cG250,
186Re-MAG3-cG250 performed as well as 90Y-SCN-Bz-
DTPA-cG250 (no significant difference) and significantly
outperformed 131I-cG250. This is in line with the results of
Kievit et al. (37), who reported similar biodistribution re-
sults for 186Re- and 131I-labeled mAb 323/A3 that resulted in
a 1.3-fold higher cumulative absorbed radiation dose in the
tumor for 186Re-labeled-323/A3. When mice were treated
with equivalent radionuclide doses, tumor growth inhibition
was also slightly better for the group injected with 186Re-
labeled 323/A3 (37). Because in our RIT experiments the
MTD of 186Re-cG250 was considerably higher than that of
131I-cG250, this might explain the observed pronounced
differences in tumor growth delay between mice treated
with 186Re-labeled and radioiodinated cG250.
Comparison of the RIT results of the current study with
data from published literature on similar RIT experiments in
nude mice is difficult, because experimental settings may
differ widely (e.g., different sizes of tumor volume treated
or various methods to dose the radiolabeled mAb). Second,
the doses used for RIT can be based on established MTDs,
FIGURE 5. Tumor volume over time in
groups treated with 131I-cG250 (A), 90Y-
ITC-Bz-DTPA-cG250 (B), 186Re-MAG3-
cG250 (C), and 177Lu-ITC-Bz-DTPA-cG250
(D).
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equivalent radionuclide doses, or even doses adjusted to
deliver equal cumulative absorbed radiation doses to the
tumor (28,34,37,38).
Although dosimetric calculations to estimate the ab-
sorbed radiation dose in the tumors can be fairly inaccurate
as a result of the inaccuracy of the models used, the relative
observed delays in tumor growth in the treatment groups
(177Lu was longer than 90Y, which was approximately equal
to 186Re, which was longer than 131I) corresponded to the
respective calculated estimates of radiation-absorbed dose
in the tumors (177Lu was greater than 186Re, which was
greater than 90Y, which was greater than 131I).
The fact that the residualizing radionuclides 90Y and 177Lu
when labeled to mAbs performed much better than conven-
tionally radiolabeled mAbs has also been demonstrated
previously (33,34). However, unlike Stein et al. (28), who
TABLE 5
Calculated Mean Delay in Exponential Tumor Growth for
RIT and Control Groups
Radioimmunoconjugate
preparation
Mean exponential tumor growth delay
(d  SD)
Unlabeled cG250 7.9  4.1
PBS 6.0  5.0
90Y-SCN-Bz-DTPA-cU36 9.6  4.4
131I-cG250 26.6  10.2
90Y-SCN-Bz-DTPA 124.5  69.1
186Re-MAG3 90.0  30.5
177Lu-SCN-Bz-DTPA 186.4  34.7
FIGURE 6. Tumor volume over time in
control groups, including those treated
with unlabeled cG250 (A), PBS (B), and 5.6
MBq (150 mCi) 90Y-cU36 (C).
FIGURE 7. Mean relative tumor growth in time for all groups
(131I-cG250, 90Y-ITC-Bz-DTPA-cG250, 186Re-MAG3-cG250,
177Lu-ITC-Bz-DTPA-cG250, unlabeled cG250, PBS, and 90Y-
cU36).
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did not find a marked difference in biodistribution and
therapeutic efficacy between 90Y- and 177Lu-labeled mAb
RS7 in a direct comparison, our RIT experiments showed
that 177Lu-SCN-Bz-DTPA-cG250 was superior even to 90Y-
SCN-Bz-DTPA-cG250. This could be explained in part by
the small size of the tumors used in the current experiments
when compared with the large, established tumors (mean
tumor volume, 0.85 cm3) in the RIT experiments performed
by Stein et al. (28). The smaller size of the tumor volumes
would be to the advantage of 177Lu as compared with 90Y,
the former being the -emitter with the lowest energy and,
therefore, better suited to irradiate small tumors. Siegel et al.
(39) and O’Donoghue et al. (40) calculated that in small
tumors a relatively large portion of the emitted energy of
90Y is deposited outside the tumor, compared with radionu-
clides with a lower-energy -emission, such as 131I or 177Lu.
Recently, De Jong et al. (3) showed that 90Y-DOTA-TYR3-
octreotide was able to induce tumor regression in rats,
especially in tumors of medium size (3–9 cm3). However, in
small tumors (1 cm3), this effect was less pronounced. In
contrast, the growth of small tumors (1 cm3) could be
prevented effectively with an identical radiation dose (60
Gy) to the tumor with 177Lu-DOTA-TYR3-octreotate, nicely
providing experimental evidence for this theory (38). In
addition, the half-life of 177Lu is better suited for the rela-
tively slow pharmacokinetics of radiolabeled whole-IgG
antibody. Blood clearance and tumor uptake of radiolabeled
cG250 are slow, and thus a higher tumor dose is obtained
with 177Lu than with 90Y.
We recently demonstrated that cG250 labeled with re-
sidualizing radionuclides had a higher uptake in RCC le-
sions in humans than does conventionally radioiodinated
cG250 (41). Depending on the size of the lesions at which
treatment is aimed (macroscopic metastases, microscopic or
small-volume disease, or in an adjuvant setting), RIT with
cG250 labeled with 90Y or 177Lu may have an impact in
patients with RCC.
CONCLUSION
These experimental RIT studies clearly showed that the
therapeutic efficacies of the cG250 preparations labeled
with 177Lu, 90Y and 186Re are superior to that of 131I-cG250.
177Lu showed the best antitumor effect, most likely as a
result of optimal radiation characteristics for small tumors
and a physical half-life that better matches mAb pharmaco-
kinetics. The present study shows that especially the residu-
alizing radionuclides 90Y and 177Lu are potentially better
candidates for RIT studies in patients with RCC than is
conventionally radiolabeled 131I using mAb cG250.
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